Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Abstract

IntroductionPatients with rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a proprietary patient support program (PSP, AbbVie Care®). The main objective of this study was to examine the effectiveness of ADA on RA treatment course over time in the context of PSP utilization.MethodsPASSION was a 78-week post-marketing observational study of RA patients with an insufficient response to ≥1 DMARD newly initiating ADA in routine clinical care that was conducted in Europe, Israel, Mexico, Puerto Rico, and Australia. One prior biologic DMARD was allowed. The primary endpoint was percentage of patients achieving the minimal clinically important difference (MCID; improvement of ≥0.22 compared to baseline) in Health Assessment Questionnaire (HAQ) Disability Index (HAQ-DI) at week 78. Additionally, multiple clinical and patient-reported outcomes (PROs) were evaluated over time. Patients were categorized based on their participation in the PSP: ever (PSP users) vs. never (PSP non-users). Safety events were monitored throughout the study.ResultsOverall, 42.8% of PSP users achieved the MCID in HAQ-DI at week 78 (improvement of at least 0.22 compared to baseline). From 1025 enrolled, 48.7% of patients were PSP users while treated with ADA. The percentage of patients achieving MCID in the HAQ-DI was higher in PSP users vs. PSP non-users (48.1 vs. 37.8%) at week 78 (p < 0.001, NRI). Most of the studied clinical outcomes and PROs showed significant improvements (p < 0.05) from baseline to week 78 favoring PSP users over PSP non-users.ConclusionsIn patients with moderate-to-severe RA who initiated ADA, improvements in clinical, functional, and PROs were achieved in real-world settings with significantly greater improvements among PSP users in comparison with PSP non-users.FundingAbbVie. Trial registration: ClinicalTrials.gov identifier, NCT01383421.

Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study

“…Our results are in line with those of Van den Bosch and colleagues [20] who previously Our study has several implications. The study results showed significant associations in improvements in patient-reported outcomes in patients with AS treated with ADA who participated in the AC-PSP, and who received tailored services in the form of continuous CCCs within 18 months.…”

Ab1236 improving Clinical Outcome and Reducing Cost for Patients With Rheumatic Diseases via Online Interaction With Rheumatologists Based on Smart System of Disease Management (Ssdm) Mobile Tool

“…The annual estimated costs of each patient were $35238.8 while the direct cost accounted for 90.2% and the cost of medication accounted for 78.6%. There were significant differences in change of ASQoL (change,3.89 [95%CI, 3.06 to 4.71]; P<0.0001) and EQ-5D (change, -0.19 [95%CI, -0.24 to -0.31]; P<0.0001) scores from baseline and 24 weeks, with more improvements after therapy compared with baseline. Cost of illness was The cost of AS patients treated with adalimumab therapy was high in China and symptoms and QoL improved significantly after therapy.…”

“…Background: The diagnosis of rheumatoid arthritis (RA) using EULAR criteria through conventional assessments remains controversial, especially for those with seronegative results, many of patients without other diagnostic aids as imaging, could be wrong diagnosed followed by expensive treatments (1)(2)(3). Objectives: To evidence through real-world data how the use of imaging within a screening process of diagnosis of RA can saving future costs for unnecessary treatments in patients with misdiagnosis of RA.…”

Ab1237 cost of Illness and Quality of Life in Ankylosing Spondylitis Patients Treated With Adalimumab in China

“…The annual estimated costs of each patient were $35238.8 while the direct cost accounted for 90.2% and the cost of medication accounted for 78.6%. There were significant differences in change of ASQoL (change, 3 Background: Adherence to therapy in chronic diseases such as inflammatory rheumatic diseases (CIRD), inflammatory bowel diseases (IBD) and psoriasis (Pso) is a major condition to achieve positive outcomes. Patient support programs (PSPs) were developed to improve the quality of care and enhance adherence to therapy.…”